HALIFAX, NOVA SCOTIA--(Marketwire - Sept. 4, 2012) - Immunovaccine Inc. (IMV.V) ("Immunovaccine" or the "Company"), a clinical stage vaccine company, today announced that the Company will present at the Rodman & Renshaw 14th Annual Healthcare Conference. The conference will take place September 10-11, 2012 at the Waldorf Astoria Hotel in New York City.
John Trizzino, chief executive officer of Immunovaccine, will present a corporate update on Tuesday, September 11, 2012 at 3:15 p.m. (Eastern) in Starlight Center. His presentation will include an overview of Immunovaccine's novel DepoVax(TM) adjuvanting delivery platform, as well as the latest developments for the Company's two clinical-stage cancer vaccines, new infectious disease vaccine candidates and multiple partnered programs in the areas of bio-defense, addiction medicine and animal health.
The presentation will be webcast live at http://www.wsw.com/webcast/rrshq22/imv.v and also on the investor's page of Immunovaccine's website at http://www.imvaccine.com/investors.php, where it will be archived for 90 days following the presentation.
Mr. Trizzino will also be available for one-on-one meetings with investors participating in the conference. If you are interested in meeting with Mr. Trizzino during the conference, please contact Stephanie Diaz of Vida Communication at 415-675-7401 or email@example.com, or Rodman & Renshaw at firstname.lastname@example.org.
Immunovaccine Inc. applies its novel vaccine delivery platform to the development of vaccines for cancer therapy and infectious diseases. The Company's DepoVax(TM) platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has advanced its platform technology and proprietary cancer vaccine into Phase I human clinical trials and has demonstrated both safety and immunogenicity potential. The Company is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Immunovaccine has several key partnerships in the animal health sector including an agreement with Pfizer Animal Health, which has licensed the Company's delivery technology platform to develop vaccines for livestock. Connect at www.imvaccine.com.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.